Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine. For more information, visit www.altoida.com.
If you’ve ever lost sleep over delayed study enrollment, consider 1nHealth your new weighted blanket. 1nHealth fills studies through a simple philosophy: Don’t waste the power of…
Leveraging over 30 years of experience working with large biopharma, emerging biotech, CROs, and healthcare companies, the strategic advisors, executives, and subject matter…
Block Clinical is intently focused on streamlining the myriad of logistics involved in traditional, virtual, and hybrid clinical trials. From globally integrated patient…